Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10596819 | Bioorganic & Medicinal Chemistry Letters | 2010 | 4 Pages |
Abstract
Exendin-4, a glucagon-like peptide 1 receptor agonist, is a potent therapeutic xenopeptide hormone for the treatment of type 2 diabetes. In order to further improve in vivo activity, we examined the introduction of sialyl N-acetyllactosamine (sialyl LacNAc) to exendin-4. The glycosylated analogue having sialyl LacNAc at position 28 was found to have improved in vivo activity with prolonged glucose-lowering activity.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Taichi Ueda, Takaomi Ito, Kazuyoshi Tomita, Hiroko Togame, Masataka Fumoto, Kenji Asakura, Takeo Oshima, Shin-Ichiro Nishimura, Kohji Hanasaki,